Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
Element79 Announces Extension to Proposed Spin Out and Merger, Mailing of Meeting Materials for Special Meeting in Connection with Previously Announced Plan of Arrangement with Synergy Metals Corp.
